ASX:PAB

Patrys (PAB) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
250,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
8.82%
Price Target
N/A
PAB stock logo

About Patrys Stock (ASX:PAB)

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.

PAB Stock News Headlines

Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
See More Headlines
Receive PAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Patrys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2019
Today
4/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-5,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.70 million

Miscellaneous

Outstanding Shares
2,060,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
0.36
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. James A. Campbell B.Sc.
    MBA, Ph.D., MD, CEO & Executive Director
  • Mr. Stefan Ross
    Company Secretary
  • Dr. Rebecca Tunstall
    Vice President of Corporate Development

PAB Stock Analysis - Frequently Asked Questions

How were Patrys' earnings last quarter?

Patrys Limited (ASX:PAB) issued its quarterly earnings data on Wednesday, February, 20th. The company reported $0.00 earnings per share (EPS) for the quarter.

What other stocks do shareholders of Patrys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Patrys investors own include Woolworths Group (WOW), Proteomics International Laboratories (PIQ), Insurance Australia Group (IAG) and Bendigo and Adelaide Bank (BEN).

This page (ASX:PAB) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners